Enterprise Value

216.8M

Cash

264.9M

Avg Qtr Burn

-29.1M

Short % of Float

10.35%

Insider Ownership

0.44%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ANX005 (IV) Details
Guillian-Barre syndrome, Autoimmune disease

Phase 3

Data readout

ANX005 (IV) Details
Brain disease, Huntington's disease

Phase 3

Initiation

ANX007 (IVT) Details
Geographic atrophy

Phase 3

Initiation

ANX005 (IV) Details
Amyotrophic lateral sclerosis, Neurodegenerative disease

Phase 2a

Update

ANX009 Details
Lupus nephritis

Phase 1b

Update

ANX105 Details
Autoimmune disease, Neurodegenerative disease

Phase 1

Data readout

ANX1502 Details
Autoimmune disease, Cold agglutinin disease

Phase 1a

Data readout

ANX005 (IV) Details
Warm autoimmune hemolytic anemia, Autoimmune disease

Failed

Discontinued